Murine mammary carcinoma cells and CD11c+ dendritic cells elicit distinct responses to lipopolysaccharide and exhibit differential expression of genes required for TLR4 signaling

Cellular Immunology

Volumn 266, Issue 1, 2010, Pages 67-75

  Palha De Sousa, Chiquita ^a   Blum, Christopher M ^a   Sgroe, Erica P ^a   Crespo, Alexander M ^a   Kurt, Robert A ^a  

^a LAFAYETTE COLLEGE   (United States)

Author keywords

Dendritic cells; LPS; Toll like receptors; Tumor cells

Indexed keywords

B7 ANTIGEN; CD14 ANTIGEN; CD86 ANTIGEN; GLYCOPROTEIN P 15095; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 2; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ARTICLE; BREAST CARCINOMA; CARCINOMA CELL; CONTROLLED STUDY; DENDRITIC CELL; GENE EXPRESSION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; UPREGULATION;

ANIMALS; ANTIGENS, CD; ANTIGENS, CD11C; ANTIGENS, CD14; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMOKINES; CYTOKINES; DENDRITIC CELLS; GENE EXPRESSION REGULATION; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIPOPOLYSACCHARIDES; MALE; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; MYELOID DIFFERENTIATION FACTOR 88; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PEPTIDOGLYCAN; RECEPTORS, INTERLEUKIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 4;

MURINAE;

EID: 77958468750     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2010.08.015     Document Type: Article

References (37)

1. Beutler B., Jiang Z., Georgel P., Crozat K., Croker B., Rutschmann S., Du X., Hoebe K. Genetic analysis of host resistance. Toll-like receptor signaling and immunity at large. Annu. Rev. Immunol. 2006, 24:353-389.
2. Alegre M.L., Leemans J., Le Moine A., Florquin S., De Wilde V., Chong A., Goldman M. The multiple facets of toll-like receptors in transplantation biology. Transplantation 2008, 86:1-9.
3. Kawai T., Akira S. TLR signaling. Cell Death Differ. 2006, 13:816-825.
4. Airhart C.L., Rohde H.N., Hovde C.J., Bohach G.A., Deobald C.F., Lee S.S., Minnich S.A. Lipid A mimetics are potent adjuvants for an intranasal pneumonic plague vaccine. Vaccine 2008, 26:5554-5561.
5. Wang B., Trippler M., Pei R., Lu M., Broering R., Gerken G., Schlaak J.F. Toll-like receptor activated human and murine hepatic stellate cells are potent regulators of hepatitis C virus replication. J. Hepatol. 2009, 51:1037-1045.
6. Monaco C., Gregan S.M., Navin T.J., Foxwell B.M., Davies A.H., Feldmann M. Toll-like recetor-2 mediates inflammation and matrix degradation in human atherosclerosis. Circulation 2009, 120:2462-2469.
7. Lee J.H., Lee B., Lee H.S., Bae E.A., Lee H., Ahn Y.T., Lim K.S., Huh C.S., Kim D.H. Lactobacillus suntoryeus inhibits pro-inflammatory cytokine expression and TLR-4-linked NF-kappaB activation in experimental colitis. Int. J. Colorectal Dis. 2009, 24:231-237.
8. Messmer D., Messmer B., Chiorazzi N. The global transcriptional maturation program and stimuli-specific gene expression profiles of human myeloid dendritic cells. Int. Immunol. 2003, 15:491-503.
9. Shen H., Tesar B.M., Walker W.E., Goldstein D.R. Dual signaling of MyD88 and TRIF is critical for maximal TLR4-induced dendritic cell maturation. J. Immunol. 2008, 181:1849-1858.
10. Wiethe C., Debus A., Mohrs M., Steinkasserer A., Lutz M., Gessner A. Dendritic cell differentiation state and their interaction with NKT cells determine Th1/Th2 differentiation in the murine model of Leishmania major infection. J. Immunol. 2008, 180:4371-4381.
11. Sato A., Iwasaki A. Induction of antiviral immunity requires Toll-like receptor signaling in both stromal and dendritic cell compartments. Proc. Natl. Acad. Sci. 2004, 101:16274-16279.
12. Golden J.M., LaCasse C.J., Simova D.V., Murphy T.R., Kurt R.A. Differential mediator production by dendritic cells upon toll-like receptor stimulation does not impact T cell cytokine expression. Immunol. Lett. 2008, 118:30-35.
13. Weck M.M., Grunebach F., Werth D., Sinzger C., Bringmann A., Brossart P. TLR ligands differentially affect uptake and presentation of cellular antigens. Blood 2007, 109:3890-3894.
14. Flacher V., Bouschbacher M., Verronese E., Massacrier C., Sisirak V., Berthier-Vergnes O., de Saint-Vis B., Caux C., Dezutter-Dambuyant C., Lebecque S., Valladeau J. Human langerhans cells express a specific TLR profile and differentially respond to viruses and Gram-positive bacteria. J. Immunol. 2006, 177:7959-7967.
15. Trichieri G., Sher A. Cooperation of Toll-like receptor signals in innate immune defence. Nat. Rev. Immunol. 2007, 7:179-190.
16. Derbigny W.A., Hong S.C., Kerr M.S., Temkit M., Johnson R.M. Chlamydia muridarum infection elicits a beta interferon response in murine oviduct epithelial cells dependent on interferon regulatory factor 3 and TRIF. Infect. Immun. 2007, 75:1280-1290.
17. Faure E., Equils O., Sieling P.A., Thomas L., Zhang F.X., Kirschning C.J., Polentarutti N., Muzio M., Arditi M. Bacterial lipopolysaccharide activates NF-kappB through toll-like receptor 4 (TLR-4) in cultured human dermal endothelial cells. Differential expression of TLR-4 and TLR-2 in endothelial cells. J. Biol. Chem. 2000, 275:11058-11063.
18. Erridge C., Spickett C.M., Webb D.J. Non-enterobacterial endotoxins stimulate human coronary artery but not venous endothelial cell activation via Toll-like receptor 2. Cardiovasc. Res. 2007, 73:181-189.
19. B.W. Stewart, P. Kleihues, (Eds.), World Cancer Report, IARC, Lyon, France, 2003.
20. Hirabayashi K., Yano J., Inoue T., Yamaguchi T., Tanigawara K., Smyth G.E., Ishiyama K., Ohgi T., Kimura K., Irimura T. Inhibition of cancer cell growth by polyinosinic-polycytidylic acid/cationic liposome complex: a new biological activity. Cancer Res. 1999, 59:4325-4333.
21. Smits E.L.J.M., Ponsaerts P., Berneman Z.N., Van Tendeloo V.F.I. The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy. The Oncologist 2008, 13:859-875.
22. Andrews E.J., Wang J.H., Winter D.C., Laug W.E., Redmond H.P. Tumor cell adhesion to endothelial cells is increased by endotoxin via an upregulation of beta-1 integrin expression. J. Surg. Res. 2001, 97:14-19.
23. Pollet I., Opina C.J., Zimmerman C., Leong K.G., Wong F., Karsan A. Bacterial lipopolysaccharide directly induces angiogenesis through TRAF6-mediated activation of NF-κB and c-Jun N-terminal kinase. Blood 2003, 102:1740-1742.
24. Voelcker V., Gebhardt C., Averbeck M., Saalbach A., Wolf V., Weih F., Sleeman J., Anderegg U., Simon J. Hyaluronan fragments induce cytokine and metalloprotease upregulation in human melanoma cells in part by signaling via TLR4. Exp. Dermatol. 2008, 17:100-107.
25. Conroy H., Marchall N.A., Mills K.H. TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumors. Oncogene 2008, 27:168-180.
26. Sun J., Shi Y.H., Le G.W., Ma X.Y. Distinct immune response induced by peptidoglycan derived from Lactobacillus sp. World J. Gastroenterol. 2005, 11:6330-6337.
27. Schmitz F., Mages J., Heit A., Lang R., Wagner H. Transcriptional activation induced in macrophages by Toll-like receptor (TLR) ligands: from expression profiling to a model of TLR signaling. Eur. J. Immunol. 2004, 34:2863-2873.
28. Teicher B.A. Malignant cells, directors of the malignant process: role of transforming growth factor-beta. Cancer Met. Rev. 2001, 20:133-143.
29. Kim S.I., Kwak J.H., Zachariah M., He Y., Wang L., Choi ME M.E. TGF-β-activated kinase 1 and TAK1-binding protein 1 cooperate to mediate TGF-β1-induced MKK3-p38 MAPK activation and stimulation of type I collagen. Am. J. Physiol. Renal Physiol. 2007, 292:1471-1478.
30. Neil J.R., Schiemann W.P. Altered TAB1:Ikb kinase interaction promotes transforming growth factor β-mediated nuclear factor-κB activation during breast cancer progression. Cancer Res. 2008, 68:1462-1470.
31. Miggin S.M., Palsson-McDermott E., Dunne A., Jefferies C., Pinteaux E., Banahan K K., Murphy C., Moynagh P., Yamamoto M., Akira S., Rothwell N., Golenbock D., Fitzgerald K.A., O'Neil L.A. NF-kB activation by the Toll-IL-1 receptor domain protein MyD88 adaptor-like is regulated by caspase-1. Proc. Natl. Acad. Sci. 2007, 104:3372-3377.
32. Saitoh T., Yamamoto M., Miyagishi M., Taira K., Nakanishi M., Fujita T., Akira S., Yamamoto N., Yamaoka S. A20 is a negative regulator of IFN regulatory factor 3 signaling. J. Immunol. 2005, 174:1507-1512.
33. De Felippo K., Henderson R.B., Laschinger M., Hogg N. Neutrophil chemokines KC and macrophage-inflammatory protein-2 are newly synthesized by tissue macrophages using distinct TLR signaling pathways. J. Immunol. 2008, 180:4308-4315.
34. Naiki Y., Michelsen K.S., Zhang W., Chen S., Doherty T.M., Arditi M. Transforming growth factor-β differentially inhibits MyD88-dependent, but not TRAM- and TRIF- dependent, lipopolysaccharide-induced TLR4 signaling. J. Biol. Chem. 2005, 280:5491-5495.
35. Huang B., Zhao J., Li H., He K., Chen Y., Mayer L., Unkeless L.J.C., Xiong H. Toll-like receptors on tumor cells facilitates evasion of immune surveillance. Cancer Res. 2005, 65:5009-5014.
36. Andervont H.B. The reaction of mice and various mouse tumours to the injection of bacterial products. Am. J. Cancer 1936, 27:77-83.
37. Parr I., Wheeler E., Alexander P. Similarities of the anti-tumour actions of endotoxin, lipid A and double-stranded RNA. Br. J. Cancer 1973, 27:370-389.